SNY - Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity Innovation | Benzinga

On Thursday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported first-quarter adjusted EPS of $9.55, down 5% Y/Y, missing the consensus of $10.10.

The company reported sales of $3.15 billion, missing the consensus of $3.22 billion.

First quarter 2024 revenues decreased by 1%; excluding Ronapreve (COVID-19 antibody), revenues increased by 7%.

Eylea US sales fell 16% to $1.2 billion, primarily due to changing market dynamics, resulting in lower volumes and a lower net selling price.

Eylea HD sales reached $200 million, and overall, Eylea sales fell 2% to $1.4 billion.

Continued Dupixent strength compensated for stagnant Eylea sales, which Sanofi SA (NASDAQ:SNY) records, jumped a currency-adjusted Full story available on Benzinga.com